139 related articles for article (PubMed ID: 19491875)
1. Use of infliximab in particular clinical settings: management based on current evidence.
Papa A; Mocci G; Bonizzi M; Felice C; Andrisani G; De Vitis I; Guidi L; Gasbarrini A
Am J Gastroenterol; 2009 Jun; 104(6):1575-86. PubMed ID: 19491875
[TBL] [Abstract][Full Text] [Related]
2. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
3. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
4. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
5. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
6. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
7. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
[TBL] [Abstract][Full Text] [Related]
8. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
10. Use of infliximab in pregnancy.
Mahadevan U; Kane S
Am J Gastroenterol; 2010 Jan; 105(1):219; author reply 219-20. PubMed ID: 20054309
[No Abstract] [Full Text] [Related]
11. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in the treatment of steroid-dependent ulcerative colitis.
Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
14. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
15. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
Ainsworth MA; Brynskov J
Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
[TBL] [Abstract][Full Text] [Related]
16. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
17. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
[TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease in adults.
Katz JA
J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
[TBL] [Abstract][Full Text] [Related]
19. [Use of infliximab in ulcerative colitis].
Tilg H; Feichtenschlager T; Knoflach P; Petritsch W; Schöfl R; Vogelsang H; Reinisch W
Z Gastroenterol; 2007 Aug; 45(8):907-11. PubMed ID: 17701864
[TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
